10x Genomics (TXG) Current Leases (2020 - 2026)

10x Genomics' Current Leases history runs 7 years deep, the most recent figure standing at $11.3 million for Q1 2026.

• In Q1 2026, Current Leases rose 19.98% year-over-year to $11.3 million; the TTM figure through Mar 2026 stood at $11.3 million (up 19.98% YoY), while the FY2025 annual figure was $11.0 million, up 18.3% from the prior year.
• Current Leases came in at $11.3 million for Q1 2026 at 10x Genomics, up from $11.0 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $11.5 million in Q4 2023 to a low of $7.6 million in Q1 2022.
• A 5-year average of $9.7 million and a median of $9.4 million in 2025 frame the typical range for Current Leases.
• Across the five-year window, Current Leases soared 88.02% in 2022 and declined 19.4% in 2024, its largest moves.
• 10x Genomics' Current Leases stood at $9.0 million in 2022, then advanced by 27.49% to $11.5 million in 2023, then retreated by 19.4% to $9.3 million in 2024, then advanced by 18.3% to $11.0 million in 2025, then grew by 3.14% to $11.3 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $11.3 million, $11.0 million, and $10.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison